



RML- Quality Assurance Program (RML-QAP)-2021
(Under RML Research Foundation Society)



Certificate Of Participation

LAB CODE - 2067

This is to certify that **Shri Mata Sheelta Devi Swarna Jayanti Diagnostic Centre**
Haryana

has successfully participated in

RML Quality Assurance Program-(Cycle-10, 2021) for
HEMATOLOGY

Dr. Bandana Mehrotra
(Program Director)

Dr. Sanjay Mehrotra
(Chief PT Coordinator)

Dr. Supriya Mehrotra
(PT Coordinator)

Mr. Jaimit Singh
(PT Coordinator)



PARTICIPANT ASSESSMENT REPORT

CYCLE - 11

JAN 2022 - DEC 2022

Provider

RML - QAP (Quality Assurance Program)
Under RML Research Foundation
B-171, Nirala Nagar,
Lucknow
India

Coordinator

Dr. Sanjay Mehrotra
Dr. Supriya Mehrotra/Mr. Jaimit Singh

Enclosed Reports :

- All Method Report
- Method Wise Participant Report
- Graphical Report
- Participants Complete Data Report

Contact us :-

Tel:- 0522-2788444, 2788666, 4034100,4077180, 7518077222

Email-Id:- rmlresearchfoundation@gmail.com
Website:- www.rmlpathology.com



Address: B-171, Nirala Nagar, Lucknow - 226 020. Ph. : 4034100-130 (30 Lines), 4077180, 2788444 Fax :(0522)2788555

Email: rmlresearchfoundation@gmail.com Website: www.rmlpathology.com

Continuous Efforts And Execution Leads To Quality Excellence



HEMATOLOGY

ALL METHOD REPORT

Cycle-11/2022

Round -2

Date: 05/04/2022

Lab Code: 2067

Complete Blood Count (CBC)

Parameters	No.of Participants	Group Mean	Standard deviation (SD)	Uncertainty of Assign Values	Range (± 2 SD)	Your Value	Standard Deviation Index(SDI)
Hb gm/dl	151	11.7	0.4	0.04	10.9-12.4	11.9	0.5
WBC × 10 ³ /μl.	151	10.1	2.4	0.24	5.3-14.8	12.2	0.9
RBC × 10 ⁶ /μl.	151	4.0	0.1	0.01	3.77-4.25	3.92	-0.8
Hct%	151	35.2	2.4	0.24	30.5-39.9	35.0	-0.1
MCV fl.	151	87.7	4.3	0.44	79.2-96.3	89.2	0.3
MCH pg.	151	29.1	1.0	0.10	27.1-31.0	30.3	1.2
MCHC gm/dl	151	33.0	2.2	0.22	28.7-37.3	34.0	0.5
Platelet × 10 ³ /μl.	151	260.5	18.5	1.88	223.6-297.5	275	0.8

Interpretation of SDI:

SDI Value(+/-)	0 - 0.5	0.6 - 0.9	1.0 - 2.0	2.1 - 2.9	≥ 3
Interpretation	Excellent Performance	Good Performance	Acceptable Performance	Marginal Performance Need Improvement	Unacceptable Performance Needs Urgent action

Peripheral Blood Smear(PBS):

	Your Result	Consensus Result
DLC	Bl-65, P-15, L-17, E-1, M-2	Bl-44.3-69.2, P-8.1-21.8, L-6.8-26.6 Pmyelo-0.1-10.7, M-1.1-5.5
Morphology	RBCs Normocytic Normochromic, target cells WBCs Blasts with punched out nucleoli some lymphoid cells are showing cleaved nuclei Platelets reduced on smear	ΔNormocytic/Normochromic (107/123) ΔThrombocytopenia (94/123) ΔBlasts (91/123) ΔLeukocytosis (55/123)
Diagnosis	Acute Leukemia	Acute Leukemia/ Acute Myeloid Leukemia (AML)

Legends	(*) Excluded From Group Mean	{.} Not Reported	(#)Late Result Submission	(\$)Reported in other Unit
---------	------------------------------	------------------	---------------------------	----------------------------

Chief Coordinator

Dr. Sanjay Mehrotra

Checked By:


Prepared by: SS

Programme Director

Dr. Bandana Mehrotra

****End of Report****

Page 1 of 5





HEMATOLOGY METHOD WISE REPORT

Lab Code: 2067

Cycle-11/2022
Round -2

Date: 05/04/2022

Note: Your lab is not the part of Method Group

Complete Blood Count (CBC)

Parameters	Method Group	No.of Participants	Group Mean	Standard deviation (SD)	Uncertainty of Assign Values	Range (± 2 SD)	Your Value	Standard Deviation Index(SDI)
Hb gm/dl	Photometric	53	11.7	0.4	0.07	11.0-12.5	-	-
WBC $\times 10^3/\mu\text{l}$.	Electrical impedance	54	10.9	1.1	0.19	8.8-13.1	-	-
RBC $\times 10^6/\mu\text{l}$.	Electrical impedance	63	4.0	0.1	0.02	3.8-4.2	-	-
Hct%	Calculated	30	35.4	2.4	0.55	30.5-40.2	-	-
MCV fl.	Electrical impedance	37	87.1	5.1	1.05	77.0-97.2	-	-
MCH pg.	Calculated	65	29.1	1.0	0.16	27.2-31.0	-	-
MCHC gm/dl	Calculated	68	33.1	2.4	0.36	28.4-37.8	-	-
Platelet $\times 10^3/\mu\text{l}$.	Electrical impedance	61	263.1	18.8	3.01	225.5-300.8	-	-

Interpretation of SDI:

SDI Value(+/-)	0 - 0.5	0.6 - 0.9	1.0 - 2.0	2.1 - 2.9	≥ 3
Interpretation	Excellent Performance	Good Performance	Acceptable Performance	Marginal Performance Need Improvement	Unacceptable Performance Needs Urgent action

Legends	(*) Excluded From Group Mean	{,} Not Reported	(#)Late Result Submission	(\$)Reported in other Unit
---------	------------------------------	------------------	---------------------------	----------------------------

Chief Coordinator

Programme Director

Dr.Sanjay Mehrotra

Dr.Bandana Mehrotra

Checked By:

****End of Report****

Page 2 of 5

Prepared By: SS









HEMATOLOGY

GRAPHICAL REPORT

Cycle - 11/2022
Round -2

Date: 05/04/2022







HEMATOLOGY

GRAPHICAL REPORT

Cycle - 11/2022
Round -2

Date: 05/04/2022



Page 2 of 2



Hematology

ALL PARTICIPANTS COMPLETE DATA REPORT

Cycle - 11/2022
Round No - 2

Date: 05/04/2022

Note:- This report is only for information about the participant's performance in the particular round

Parameters	Total No. of Participants	No. of Responses	No of Participant Excluded from Group Mean	No. of Participants SDI b/w 0.0 - 2	No. of Participants SDI b/w 2.1 - 2.9	No. of Participants SDI >3
Hb gm/dl	175	151	5	140	3	8
WBC $\times 10^3/\mu\text{l}$.	175	151	7	137	5	9
RBC $\times 10^3/\mu\text{l}$.	175	151	4	129	10	12
HCT%	175	151	1	141	8	2
MCV fl.	175	151	2	143	5	3
MCH pg.	175	151	4	139	6	6
MCHC gm/dl	175	151	0	141	4	6
Platelet $\times 10^3/\mu\text{l}$.	175	151	1	136	11	4

****End of Report****

Page 5 of 5



Address: B-171, Nirala Nagar, Lucknow - 226 020. Ph. : 4034100-130 (30 Lines), 4077180, 2788444 Fax : (0522)2788555

Email: rmlresearchfoundation@gmail.com Website: www.rmlpathology.com

Continuous Efforts And Execution Leads To Quality Excellence